Compare MasTec Inc (MTZ) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Sana Biotechnology Inc — how do they compare? MasTec Inc trades at $212.75 (market cap $17.40B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: MasTec Inc is far larger — about 20.8× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is more actively traded (4,507,444 versus 1,415,821). Which is the better fit depends on your goals — on Pluang, investors hold MasTec Inc for 23 Days and Sana Biotechnology Inc for 23 Days on average.
| MTZ | SANA | |
|---|---|---|
Market Cap | $17.40B | $836.71M |
Volume | 1,415,821 | 4,507,444 |
Sector | Industrials | Health |
52-Week High | $437.51 | $5.92 |
52-Week Low | $190.08 | $2.68 |
Typical Hold Time | 23 Days | 23 Days |
Enterprise Value | $20.32B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $214.84, down 3.82% on the day, with a bearish technical signal despite strong analyst support. The stock shows mixed earnings performance with recent beats but a Q2 2026 miss, while fundamentals reveal solid revenue growth and profitability metrics. The company benefits from record backlog and infrastructure demand, particularly in power delivery and data center markets.
MTZ presents a compelling long-term opportunity with 89% analyst buy ratings and a $408.58 consensus target, though premium valuation and weak cash flow pose risks. Infrastructure spending tailwinds and AI-driven demand support growth, but execution challenges and communications segment softness require monitoring.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
